<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/22/3315046/0/en/Press-Release-Sanofi-appoints-Paulo-Fontoura-as-Global-Head-of-R-D.html">Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&amp;D</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi a ppoints  Paulo Fontoura   as   Global  Head of  R&amp;D Paris ,  June 22 ,   2026. Sanofi today announced the appointment of Paulo F o ntoura ,  MD, PhD, FAAN,   as  Executi v e Vice President, Global  Head of Research &amp; Development  Pharma, effective September 1, 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/19/3314694/0/en/Press-Release-Sanofi-s-Sarclisa-subcutaneous-formulation-approved-in-Japan-for-patients-with-multiple-myeloma.html">Press Release: Sanofi&#39;s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi&#39;s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IV Second global approval for Sarclisa SC following the EU Paris, June 19, 2026. The Ministry of Health, Labour and Welfare in Japan has g...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/15/3312003/0/en/Sanofi-Information-concerning-the-total-number-of-voting-rights-and-shares-May-2026.html">Sanofi: Information concerning the total number of voting rights and shares – May 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l&#39;Autorité des Marchés Financiers (Regulation of the French stock market authority)
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/fda-approves-sanofis-drug-stage-3-type-1-diabetes-children-2026-06-12/">FDA approves Sanofi&#39;s drug for stage 3 type 1 diabetes in children</a>
    </div>

      <div class="me-0 me-md-5">
        The U.S. ​Food and ‌Drug Administration approved ​Sanofi&#39;s ​injection to slow ⁠the loss ​of ​the body&#39;s own insulin production ​in ​children aged 8 ‌to ⁠17 years recently diagnosed ​with ​stage ⁠3 type ​1 ​diabetes, ⁠the agency said ⁠on ​Friday.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/12/3311029/0/en/Wayrilz-rilzabrutinib-Sanofi-Positioned-to-Define-Third-Line-Treatment-in-Warm-Autoimmune-Hemolytic-Anemia-w-AIHA-as-IMAAVY-niopcalimab-Jonhson-Johnson-Follows-Closely-with-Positiv.html">Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson &amp; Johnson) Follows Closely with Positive Data Announcement at EHA 2026</a>
    </div>

      <div class="me-0 me-md-5">
        New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time. New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refra...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negativ
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/news/technology/sanofi-stock-dianthus-therapeutics-argenx-cidp-treatment/">Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/sanofi-ends-phase-3-riliprubart-trial-after-weak-interim-results-2026-06-10/">Sanofi ends Phase 3 riliprubart trial after weak interim results</a>
    </div>

      <div class="me-0 me-md-5">
        Biopharmaceutical company Sanofi will stop a Phase ​3 trial of its drug ‌riliprubart for a rare neurological condition after an interim ​analysis of the ​study found it unlikely to ⁠provide sufficient efficacy.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negativ
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Sanofi-FR0000120578">Sanofi</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/sanofi-to-stop-late-stage-study-of-immune-disorder-drug-1f05296c">Sanofi to Stop Late-Stage Study of Immune-Disorder Drug</a>
    </div>

      <div class="me-0 me-md-5">
        The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Sanofi-FR0000120578/load_more?page=5">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>